Mural Oncology (MURA) Competitors $4.05 -0.17 (-4.03%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.04 -0.01 (-0.25%) As of 02/21/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MURA vs. ATYR, IMMP, OLMA, KRRO, NMRA, YMAB, KOD, TVGN, NGNE, and ACIUShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Korro Bio (KRRO), Neumora Therapeutics (NMRA), Y-mAbs Therapeutics (YMAB), Kodiak Sciences (KOD), Tevogen Bio (TVGN), Neurogene (NGNE), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Atyr PHARMA Immutep Olema Pharmaceuticals Korro Bio Neumora Therapeutics Y-mAbs Therapeutics Kodiak Sciences Tevogen Bio Neurogene AC Immune Atyr PHARMA (NASDAQ:ATYR) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends. Does the MarketBeat Community believe in ATYR or MURA? Atyr PHARMA received 7 more outperform votes than Mural Oncology when rated by MarketBeat users. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes12100.00% Underperform VotesNo VotesMural OncologyOutperform Votes5100.00% Underperform VotesNo Votes Is ATYR or MURA more profitable? Mural Oncology's return on equity of -70.10% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% Mural Oncology N/A -70.10%-61.30% Which has more volatility & risk, ATYR or MURA? Atyr PHARMA has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3.9, indicating that its stock price is 290% more volatile than the S&P 500. Do analysts rate ATYR or MURA? Atyr PHARMA currently has a consensus target price of $18.60, suggesting a potential upside of 330.56%. Mural Oncology has a consensus target price of $16.00, suggesting a potential upside of 295.06%. Given Atyr PHARMA's higher probable upside, equities analysts plainly believe Atyr PHARMA is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Mural Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer ATYR or MURA? In the previous week, Atyr PHARMA had 11 more articles in the media than Mural Oncology. MarketBeat recorded 14 mentions for Atyr PHARMA and 3 mentions for Mural Oncology. Atyr PHARMA's average media sentiment score of 0.89 beat Mural Oncology's score of 0.21 indicating that Atyr PHARMA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atyr PHARMA 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mural Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in ATYR or MURA? 61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 80.2% of Mural Oncology shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by company insiders. Comparatively, 0.1% of Mural Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, ATYR or MURA? Atyr PHARMA has higher revenue and earnings than Mural Oncology. Atyr PHARMA is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$350K1,036.06-$50.39M-$0.94-4.60Mural OncologyN/AN/A-$207.45M-$9.14-0.44 SummaryAtyr PHARMA beats Mural Oncology on 10 of the 14 factors compared between the two stocks. Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.83M$7.06B$5.84B$9.14BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.9318.2614.95Price / SalesN/A281.18434.4770.76Price / CashN/A65.9238.4235.17Price / Book0.266.717.644.65Net Income-$207.45M$138.11M$3.18B$245.69M7 Day Performance-5.59%-2.54%-1.95%-2.68%1 Month Performance2.53%-2.00%-0.23%-2.16%1 Year Performance-12.90%-5.04%16.69%12.90% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology3.5982 of 5 stars$4.05-4.0%$16.00+295.1%-13.6%$71.83MN/A-0.44119ATYRAtyr PHARMA2.8123 of 5 stars$3.41-5.0%$19.25+464.5%N/A$286.24M$350,000.00-3.6353Analyst ForecastAnalyst RevisionNews CoverageGap UpIMMPImmutep0.9684 of 5 stars$1.96+0.5%$8.50+333.7%-13.9%$285.30M$5.14M0.002,021Upcoming EarningsOLMAOlema Pharmaceuticals3.2688 of 5 stars$4.97+2.9%$28.75+478.5%-64.0%$284.78MN/A-2.2770KRROKorro Bio0.9143 of 5 stars$30.02+3.2%$144.00+379.7%-51.4%$281.29MN/A0.0070News CoverageGap UpNMRANeumora Therapeutics4.074 of 5 stars$1.74+3.0%$16.50+848.3%-90.0%$281.11MN/A-0.93108News CoverageYMABY-mAbs Therapeutics2.5862 of 5 stars$6.24+1.1%$20.89+234.8%-65.3%$279.49M$84.82M-11.56150News CoverageKODKodiak Sciences4.253 of 5 stars$5.26+3.1%$8.00+52.1%-14.6%$276.78MN/A-1.4490Positive NewsTVGNTevogen Bio3.4266 of 5 stars$1.58+1.3%$4.20+165.8%-82.1%$276.58MN/A0.003NGNENeurogene2.2542 of 5 stars$18.42-1.9%$60.83+230.3%-41.7%$273.63M$925,000.000.0090ACIUAC Immune2.2147 of 5 stars$2.74+2.2%$12.00+338.0%-21.0%$271.10M$16.48M-5.96140News CoveragePositive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Atyr PHARMA Competitors Immutep Competitors Olema Pharmaceuticals Competitors Korro Bio Competitors Neumora Therapeutics Competitors Y-mAbs Therapeutics Competitors Kodiak Sciences Competitors Tevogen Bio Competitors Neurogene Competitors AC Immune Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MURA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
